Antineoplastic therapy combined with whole brain radiation compared with whole brain radiation alone for brain metastases: A systematic review and meta-analysis

European Review for Medical and Pharmacological Sciences

Volumn 17, Issue 6, 2013, Pages 777-787

  Meng, F L ^a   Zhou, Q H ^a   Zhang, L L ^a   Ma, Q ^a   Shao, Y ^a   Ren, Y Y ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Antineoplastic; Brain metastases; Meta analysis; Systematic review; Whole brain radiation

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; GADOLINIUM TEXAPHYRIN; NIMUSTINE; SEMUSTINE; TEGAFUR; TEMOZOLOMIDE; THALIDOMIDE; TOPOTECAN;

ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CAUSE OF DEATH; CENTRAL NERVOUS SYSTEM DISEASE; DATA BASE; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; META ANALYSIS; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE; SYSTEMATIC REVIEW; THERAPY EFFECT; TREATMENT RESPONSE; WHOLE BRAIN RADIATION;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84878569196     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. POSNER JB. Neurologic complications of cancer. Ann Oncol 1998; 9: 232.
2. POSNER JB. Brain metastases: a brief revie. J Neurooncol 1996; 27: 287-293.
3. SUNDSTORM JT, MINN H, LERTOLA KK. Prognosis of patients treated for intracranial metastases with whole-brain irradiation. Ann Med 1998; 30: 296-299.
4. PATCHELL RA, TIBBS PA, WALSH JW. A randomized trial of surgery in the treatment of single metastases of the brain. N Engl J Med 1990: 322: 494-500.
5. CHO KH, HALL WA, GERBI BJ. Patient selection criteria for the treatment of brain metastases with stereotactic radiosurgery. J Neurooncol 1998; 40: 73-86.
6. LI J, BENTZEN SM, RENSCHLER M. Regression of brain metastases after whole brain radiation therapy correlates with survival and improved neurocognition function with brain metastases. J Clin Oncol 2007; 10: 1260-1266.
7. NIEDER C, GROSU AL, ASTNER S, TSTNER S. Integration of chemotherapy into current treatment strategies for brain metastases from solid tumors. Radiat Oncol 2006; 1: 19.
8. VAN DEN BENT MJ. The role of chemotherapy in brain metastases. Eur J Cancer 2003; 39: 2114-2120.
9. VERGER E, GIL M, YAYA R. Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial. Int J Radiat Oncol Biol Phys 2005; 61: 185-191.
10. NEUHAUS T, KO Y, MULLER RP. A phase III trial of topotecan and whole brain radiation therapy for patients with CNS-metastases due to lung cancer. Br J Cancer 2009; 100:291-297.
11. ROBINET G, THOMAS P, BRETON JL. Results of a phase III study of early versus delayed whole brain radiotherapy with cocurrent cisplatin and vinorelbine combination in inoperable brain metastasis of nonsmall cell lung cancer. Ann Oncol 2001; 12: 59-67.
12. USHIO Y, ARITA N, HAYAKAWA T. Chemotherapy of brain metastases from lung carcinoma: a controlled randomized study. Neurosurgery 1991; 28: 201-205.
13. GUERRIERI M, WONG K, RYAN G. A randomized phase III study of palliative radiation with concomitant carboplatin for brain metastases from non-small cell carcinoma of the lung. Lung Cancer 2004; 46: 107-111.
14. PRESTA M, DELL'ERA P, MITOLA S. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005; 16: 159-178.
15. AIGNER A, BUTSCHEID M, KUNKEL P. An FGF-inding protein exerts its biological function by parallel paracrine stimulation of tumor cell and endothelia cell proliferation through FGF-2 release. Int J Cancer 2001; 92: 510-517.
16. GEITZ H, HANDT S, ZWINGENBERGER K. Thelidomide selectively modulates the density of cell surface molecules involved in the adhension cascade. Immunopharmacology 1996; 31: 213-221.
17. LECANE P, KARAMAN MW, SIRISWSD M. Motexafin gadolimum and zinc indece oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res 2005; 65: 11676-11688.
18. MEHTA MP, RODRIGUS P, TERHAARD CH, RAO A, SUH J, ROA W. Survival and neurological outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 2003; 13: 2529-2536.
19. MEHTA MP, SHAPIRO WR, PHAN SC, GERVAIS R, CARRIE C, CHABOT P. Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial. Int J Radiat Oncol Biol Phys 2009; 73: 1069-1076.
20. ANTONADOU D, PARASKEVAIDIS M, SARRIS G. Phase II randomized trial of Temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 2002; 20: 3644-3650.
21. KNISELY JP, BERKEY B, CHAKRAVARTI A, YUNG AW, CURRAN WJ JR, ROBINS HI. A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RROG 0118). Int J Radiat Oncol Biol Phys 2008; 71: 79-86.
22. CHUA D, KRZAKOWSKI M, CHOUAID C, PALLOTTA MG, MARTINEZ JI, GOTTFRIED M. Throuvalas N Wholebrain radiation therapy plus concomitant temozolomide for the treatment of brain metastases from non-small-cell lung cancer: a randomized, open-lable phase II study. Clin Lung Cancer 2010; 11: 176-181.
23. CHAO J, PHILLIP R, NICKSON J. Roentgen-ray therapy for cerebral metastases. Cancer 1954; 7: 682-689.
24. SUH JH, STEA B, NABID A. Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases. J Clin Oncol 2006; 24: 106-114.
25. ANDREWS DW, SCOTT CB, SPERDUTO PW. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004; 363: 1665-1672.
26. KONDZIOLKA D, PATEL A, LUNXFORD LD. Sereotacic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys 1999; 45: 427-434.
27. HORTON J, BAXTER DH, OLSON KB. The management of metastases to the brain by irradiation and corticosteroids. Am J Roentgenol Radium Ther Nucl Med 1971; 111: 334-336.
28. BORGELT B, GELBER R, KRAMER S. The palliation of brain metases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1980; 6: 1-9.
29. CHATANI M, MATAYOSHI Y, MASAKI N. Radiation therapy for brain metastases from lung carcinoma. Prospective randomized trial according to level of lactate dehydrogenase. Strahlenther Onkol 1994; 70: 155-161.
30. STUPP R, OSTERMAN S, LEYVRAZ S. Cerebrospinal fluid levels of temozolomide as a surrogate marker for brain penetration. Proc Am Soc Clin Oncol 2001; 20: 232.
31. SUNG C, BLANEY SM, COLE DE. A pharmacokinetic model of toptecan from plasm and cerebrospinal fluid. Cancer Res 1994; 54: 5118-5122.
32. KIM JH, KIN SH, KOLOZSVARY A. Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I. Int J Radiat Oncol Biol Phys 1992; 22: 515-518.
33. GROEN H, SLEIJFER S, MEIJER C. Carboplatin and cisplatin induced potentialtation of moderate-dose radiation cytotoxicity in human lung cancer cell line. Br J Cancer 1995; 72: 1406-1411.
34. HASEGAWA H, SHAPIRO WR, POSNER JB. Chemotherapy of experimental metasteses brain tumors in female Wistar rats. Cancer Res 1979; 39: 2691-2697.
35. KOHNO T, SHITARA N, TAKAKURA K. Role of FT-207 in the treatment of metastases brain tumors. Acta Neurochir (Wien) 1976; 35: 123-133.
36. CORN BW, MOUGHAN J, KNISELY JP. Prospective evaluation of quality of life and neurocognitive effects in patients with multiple brain metastases receiving whole-brain radiotherapy with or without thalidomide on Radiation Therapy Oncology Group (RTOG) trial 0118. Int J Radiat Oncol Biol Phys 2008; 71: 71-78.
37. FINE HA, FIGG WD, JAECKLE K. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 2000; 18: 708-715.
38. CARDE P, TIMMERMAN R, MEHTA MP. Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. J Clin Oncol 2000; 18: 708-715.
39. CLARK TE, EDOM N, LARSON J. Thalomid(thalidomide) capsules: A review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing. Drug Saf 2001; 24: 87-117.
40. WEITZNER MA. Psychosocial and neuropsyciatric aspects of patients with primary brain tumors. Cancer Invest 1999; 17: 285-291; discussion 296-297.
41. REGINE WF, HUHN JL, PATCHELL RA. Risk of symptomatic brain tumor recurrence and neurologic deficit after radiosurgery alone in patients with newly diagnosed brain metastases. Results and implications. Int J Radiat Oncol Biol Phys 2002; 52: 333-338.